Literature DB >> 17908278

Plasma intercellular adhesion molecule-1 and von Willebrand factor in primary graft dysfunction after lung transplantation.

M Covarrubias1, L B Ware, S M Kawut, J De Andrade, A Milstone, A Weinacker, J Orens, V Lama, K Wille, S Bellamy, C Shah, E Demissie, J D Christie.   

Abstract

Primary graft dysfunction (PGD), a form of acute lung injury occurring within 72 h following lung transplantation, is characterized by pulmonary edema and diffuse alveolar damage. We hypothesized that higher concentrations of intercellular adhesion molecule-1 (ICAM-1) and von Willebrand factor (vWF) would be associated with the occurrence of PGD. A total of 128 lung transplant recipients among 7 lung transplant centers were enrolled in a multicenter, prospective, cohort study. Blood specimens were collected preoperatively and at 6, 24, 48 and 72 h following lung transplantation. The primary outcome was Grade 3 PGD at 72 h after transplant. Logistic regression and generalized estimating equations (GEE) were used to analyze plasma ICAM-1 and vWF. At each postoperative timepoint, mean plasma ICAM-1 concentrations were higher for patients with PGD versus no PGD. The GEE contrast estimate for the association of plasma ICAM-1 with PGD was 107.5 ng/mL (95% CI 38.7, 176.3), p = 0.002. In the multivariate analyses, this finding was independent of all clinical variables except pulmonary artery pressures prior to transplant. There was no association between plasma vWF levels and PGD. We conclude that higher levels of plasma ICAM-1 are associated with PGD following lung transplantation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17908278     DOI: 10.1111/j.1600-6143.2007.01981.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  29 in total

1.  Objective Estimates Improve Risk Stratification for Primary Graft Dysfunction after Lung Transplantation.

Authors:  R J Shah; J M Diamond; E Cantu; J Flesch; J C Lee; D J Lederer; V N Lama; J Orens; A Weinacker; D S Wilkes; D Roe; S Bhorade; K M Wille; L B Ware; S M Palmer; M Crespo; E Demissie; J Sonnet; A Shah; S M Kawut; S L Bellamy; A R Localio; J D Christie
Journal:  Am J Transplant       Date:  2015-04-15       Impact factor: 8.086

2.  Elevated plasma long pentraxin-3 levels and primary graft dysfunction after lung transplantation for idiopathic pulmonary fibrosis.

Authors:  J M Diamond; D J Lederer; S M Kawut; J Lee; V N Ahya; S Bellamy; S M Palmer; V N Lama; S Bhorade; M Crespo; E Demissie; J Sonett; K Wille; J Orens; P D Shah; A Weinacker; D Weill; B A Kohl; C C Deutschman; S Arcasoy; A S Shah; J A Belperio; D Wilkes; J M Reynolds; L B Ware; J D Christie
Journal:  Am J Transplant       Date:  2011-08-22       Impact factor: 8.086

3.  Preoperative plasma club (clara) cell secretory protein levels are associated with primary graft dysfunction after lung transplantation.

Authors:  R J Shah; N Wickersham; D J Lederer; S M Palmer; E Cantu; J M Diamond; S M Kawut; V N Lama; S Bhorade; M Crespo; E Demissie; J Sonett; K Wille; J Orens; A Weinacker; P Shah; S Arcasoy; D S Wilkes; J D Christie; L B Ware
Journal:  Am J Transplant       Date:  2014-01-08       Impact factor: 8.086

4.  Elevated plasma clara cell secretory protein concentration is associated with high-grade primary graft dysfunction.

Authors:  J M Diamond; S M Kawut; D J Lederer; V N Ahya; B Kohl; J Sonett; S M Palmer; M Crespo; K Wille; V N Lama; P D Shah; J Orens; S Bhorade; A Weinacker; E Demissie; S Bellamy; J D Christie; L B Ware
Journal:  Am J Transplant       Date:  2011-02-07       Impact factor: 8.086

5.  Postoperative estradiol levels associate with development of primary graft dysfunction in lung transplantation patients.

Authors:  Julie A Bastarache; Joshua M Diamond; Steven M Kawut; David J Lederer; Lorraine B Ware; Jason D Christie
Journal:  Gend Med       Date:  2012-02-22

6.  Effect of single vs bilateral lung transplantation on plasma surfactant protein D levels in idiopathic pulmonary fibrosis.

Authors:  Michael W Sims; Michael F Beers; Vivek N Ahya; Steven M Kawut; Karen D Sims; David J Lederer; Scott M Palmer; Keith Wille; Vibha N Lama; Pali D Shah; Jonathan B Orens; Sangeeta Bhorade; Maria Crespo; Ann Weinacker; Ejigayehu Demissie; Scarlett Bellamy; Jason D Christie; Lorraine B Ware
Journal:  Chest       Date:  2011-02-24       Impact factor: 9.410

7.  Latent class analysis identifies distinct phenotypes of primary graft dysfunction after lung transplantation.

Authors:  Rupal J Shah; Joshua M Diamond; Edward Cantu; James C Lee; David J Lederer; Vibha N Lama; Jonathan Orens; Ann Weinacker; David S Wilkes; Sangeeta Bhorade; Keith M Wille; Lorraine B Ware; Scott M Palmer; Maria Crespo; A Russell Localio; Ejigayehu Demissie; Steven M Kawut; Scarlett L Bellamy; Jason D Christie
Journal:  Chest       Date:  2013-08       Impact factor: 9.410

8.  Genetic variation in the prostaglandin E2 pathway is associated with primary graft dysfunction.

Authors:  Joshua M Diamond; Tatiana Akimova; Altaf Kazi; Rupal J Shah; Edward Cantu; Rui Feng; Matthew H Levine; Steven M Kawut; Nuala J Meyer; James C Lee; Wayne W Hancock; Richard Aplenc; Lorraine B Ware; Scott M Palmer; Sangeeta Bhorade; Vibha N Lama; Ann Weinacker; Jonathan Orens; Keith Wille; Maria Crespo; David J Lederer; Selim Arcasoy; Ejigayehu Demissie; Jason D Christie
Journal:  Am J Respir Crit Care Med       Date:  2014-03-01       Impact factor: 21.405

9.  Preoperative echocardiographic-defined moderate-severe pulmonary hypertension predicts prolonged duration of mechanical ventilation following lung transplantation for patients with COPD.

Authors:  Jeremy P Wrobel; Bruce R Thompson; Gregory I Snell; Trevor J Williams
Journal:  Lung       Date:  2012-10-12       Impact factor: 2.584

Review 10.  Soluble intercellular adhesion molecule-1 and clinical outcomes in patients with acute lung injury.

Authors:  Carolyn S Calfee; Mark D Eisner; Polly E Parsons; B Taylor Thompson; Edward R Conner; Michael A Matthay; Lorraine B Ware
Journal:  Intensive Care Med       Date:  2008-08-01       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.